Daily Archives: May 6, 2022

Senior leaders in science, government, and industry recruited for international Manhattan Project for the Brain

DUBAI, United Arab Emirates & PALO ALTO, Calif. & MONTREAL(BUSINESS WIRE)March 22, 2022

Neurotechnology Powerhouse NeuroVigil (ranked Top 10 most innovative companies in health care by Washington Post and Fast Company) announced at the New Technology & Mental Health Conference keynote during Dubais World Expo that it has recruited senior captains of industry, government and academia to scale operations leading up to the launch of its newest non-invasive iBrain brain monitor, designated by the New York Times as an innovation which will change your tomorrow.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220322005998/en/

iBrain is the worlds smallest non-invasive brain monitor. The device itself is no bigger than a car key. The first generation iBrain was released by NeuroVigil in 2009 and since then, the potential for the device has only grown. In 2011 the technology was adapted for use in Amyotrophic Lateral Sclerosis (ALS) research at the request of NeuroVigil Scientific Advisory Board member, the late Dr. Stephen Hawking. As early as 2013, an individual with ALS was able to spell with iBrain and without any implant of any kind. The new iBrain will be used to accelerate this communication and to collect data from asymptomatic individuals to expedite the hunt for predictive biomarkers of Parkinsons Disease, brain cancer and drug overmedication, as well as to track brain state, sleep and drug response in the ICU.

NeuroVigils growth team of superstar experts were handpicked by its Chairman, CEO, Founder, Dr. Philip Low.

The team is headlined by many seasoned veterans including Dr. Gabriel Vargas, the Berkeley and UCSF-trained former Head of Neuroscience Biomarkers at Roche and of Neuroscience, Early Development at Amgen; Noam Ziv, the Technion-trained Former Qualcomm VP of Technology; Hans-Peter Goertz, a former economist at Roche and Novartis; Devin Goodman, who led Technology Operations for Andrew Yangs Presidential Campaign; EEG specialist at a major US hospital, Cody Holland; European entrepreneur Boris Blatnik; and the former head of the Institute for Quantum Computing in Waterloo, Canada, Dr. David Fransen, who has also previously held the position of Consul General of Canada, in Los Angeles. Stanford and University of California luminaries and NeuroVigil advisory board members, Prof. Kwabena Boahen, a father of modern neuromorphic engineering, Prof. Utkan Demirci, an authority in the fields of cancer detection, synthetic biology and point-of-care diagnostics, Prof. Patrick Mercier, MIT-trained world-class bioengineer, and Dr. Michael Castro, a Columbia-trained internationally renowned medical and Neuro-oncologist have all joined the effort.

The team will help the company scale its Manhattan Project for the Brain, a growing international conglomerate designed to accelerate the development of neurotechnology innovations and assist elite universities in leveraging their intellectual capital and support companies built on peer-reviewed science and clinical data, rather than on promises by marketing gurus. Wilson Sonsini Goodrich & Rosati and Kilpatrick Townsend, premier Silicon Valley and intellectual property law firms, respectively, as well as the University of Waterloo, the largest international supplier of software talent to Silicon Valley, San Diegos Launch Factory accelerator, and Wyomings Health Innovation Living Laboratory (Wyoming is the projects Los Alamos where many new technologies are to be beta-tested) are strategic partners. Conversations are ongoing with Johns Hopkins, the University of California, as well as Stanford and MIT where Dr. Low has held dual positions as an Adjunct Professor and Research Affiliate, respectively. Following Dr. Lows keynote address, Montreal committed up to $10M in initial services to the conglomerate across medical partners, including the Health Innovation District, LeoMed, Inc. and CHUM, Montreals University Hospital, designated by the US News & World Report as Canadas Most Innovative Hospital.

The Salk Institute, as well as two of its presidents, including Nobel Laureate Roger Guillemin, and another international innovative hospital are shareholders. Elite venture capitalists Dr. Howard Morgan, co-founder of First Round Capital and Renaissance Technologies and the first investor in Uber, and Timothy C. Draper, co-founder of Draper Associates and DFJ, law firm DLA Piper, two co-founders of Qualcomm and a former chairman of Tesla also invested in the company, which has never accepted any federal support, and which went to the market as early as 2009 with a research contract with Roche followed by another one with Novartis the company is currently in discussions regarding a research contract with a third Swiss Pharma company regarding ALS, brain cancer and Parkinsons.

I know of a no more driven, bright, focused and experienced collection of people, some whom I met across the table while negotiating, assembled towards a common cause since the original Manhattan Project, said Dr. Low during this keynote address. The upshot of our collective work, in my opinion, besides assisting people who need it the most, will be better health and, ultimately, the ushering of the Brain Age: billions of asymptomatic people and their physicians seamlessly accessing their brain health in real-time, without any surgery or hospitalization, thanks to a constellation of non-invasive, cruelty-free, wireless, affordable and precise brain technologies.

I first met Dr. Low over 10 years ago when I was head of CNS Biomarkers at Roche in Basel. At that time, I was already able to appreciate the enormous power and promise of NeuroVigils technology. Dr. Low has a grand ambitious vision to better humanity through a technology which enables us to monitor brain health non-invasively and also allows communication through thoughts alone. Although this sounds like an improbable vision, Philip has the right mix of strong scientific training, unusual intelligence and chutzpah to make this endeavor successful, said Dr. Gabriel Vargas, incoming Chief Medical Officer of NeuroVigil.

Dr. Lows bold dissertation thesis literally created a new paradigm for the study of brain waves. So far, the iBrain has proven to be an invaluable adjunct to pharmacological clinical trial research. Unintended adverse drug side effects involving the nervous system can now be identified sooner and at a significantly reduced cost to the developer. Yet, despite NeuroVigils success to date, I believe the most significant applications of this technology are yet to come. The future will see home-based biometrics becoming a central feature of modern medical practice as screening, monitoring and tracking of innovative health data evolve into standard components of the electronic medical record. Central to these assessments will be a brain health status measurement that has both diagnostic and prognostic validity, and given their prominence in this area, NeuroVigil will likely be the industry leader, predicted Dr. Mario Orlandi, Executive Director, Technology Assessment, Johnson & Johnson, as early as 2012. He was echoed in his comments at the time by Dr. Baltazar Gomez-Mancilla, Executive Director of Neuroscience and Translational Medicine at Novartis: NeuroVigil is now expanding quickly and attracting qualified personnel in the US and overseas The company has strong science, good leadership and a bold vision.

About Dr. Philip Low

Is an Austria-born Canadian mathematician and computational neuroscientist, inventor and industrialist. He started his research career at Harvard Medical School as a teenager and went on to write a 1- page PhD thesis, at the recommendation of Dr. Francis Crick, Nobel Laureate of DNA fame, which revolutionized dynamic brain activity mapping. He has 5 dozen international patents to his name and is also globally known as the author of the historic Cambridge Declaration on Consciousness, the first formal document ratified by professional neuroscientists to acknowledge the existence of non-human consciousness. Among many other honors, Dr. Low was recognized by The Scientist Magazine as a Scientist to Watch and by MIT Technology Review as one of the Top Young Innovators in the world, an honor shared with the founders of Google and Facebook.

About NeuroVigil, Inc.

NeuroVigil, Inc. is a global neurotechnology pioneer which develops proprietary non-invasive brain monitors and advanced machine learning algorithms to detect a constellation of biomarkers of pathologies in asymptomatic individuals, such as people with neurodegeneration, adverse drug side effects or brain cancer, and to ascertain intent in individuals who cannot otherwise communicate. This arsenal of technologies does not require any non-human animal experimentation. Since its introduction on the market in 2009, the company has built momentum through research contracts with elite pharmaceutical companies, and now spearheads a growing international preventive health conglomerate of leading innovators and entrepreneurs. The company was founded and is led by Dr. Philip Low. For more information, please visit http://www.neurovigil.com.

About HEALTH INNOVATION DISTRICT (HID)

Located in the heart of the smart city of Montreal, the Health Innovation District is made up of institutions and companies that are leaders in their fields of expertise. From hospitals to startups and well-known organizations, the HID brings together a multitude of actors dedicated to transforming health care for the greater good. Right here, right now and tomorrow!

Mission

The mission of the Health Innovation District is to meet the needs of all stakeholders through innovative approaches in order to promote health care innovation and create social and economic wealth for the benefit of the population.

Vision

To team up with its partners and mobilize Quebecs creative and innovative energies to gather and share expertise in:

About LeoMed, Inc.

LeoMed is a customizable health monitoring platform. Through it, health professionals have access to hundreds of connected biometric devices as well as a no-code care journey creator. Care teams can improve patient engagement and outcomes via personalized communication pathways, questionnaires, tasks and videos. LeoMed takes a unique approach to health monitoring. It doesnt impose a way to do healthcare; it empowers care teams, researchers, and administrators to do it their way. With a team of experts with more than 20 years in the clinical field, telehealth, IT, and cybersecurity along with a strong board from public and private background, LeoMed has the experience to help institutions meet their monitoring objectives. For more information, visit http://www.leomed.co, or contact LeoMed at info@leomed.co

About CHUM

The Centre hospitalier de lUniversit de Montreal (CHUM) is an innovative hospital devoted to serving patients and the Quebec population. The CHUM adopts an integrated approach to health and the population which is expressed in all aspects of its mission such as, care, teaching, research, management, and innovation, as well as in partnership with the patient and citizen.

To achieve the objective of continuous improvement in the health of the population, management of the care trajectory and the life trajectory of patients has been implemented using data analyzed by artificial intelligence from genetic and environmental information. In collaboration with other speakers in the health and social services network (RSSS), the CHUM offers the best specialized care and services based on constantly updated scientific knowledge.

Our Mission

Providing the best specialized and ultra-specialized healthcare for all citizens of QuebecIdentifying patients needs and developing knowledge and innovative solutions through researchActively participating in education of current and future health-care professionalsTransmitting knowledge and know-how to healthcare network stakeholders to promote health and well-being to the patients and the populationAssessing health innovative technologies and interventionsDeveloping a healthy environment that integrates innovation and carbon neutrality

View source version on businesswire.com: https://www.businesswire.com/news/home/20220322005998/en/

For inquiries: press@neurovigil.com ATTN Stanley Barton or +1-514-890-8000, Ext. 31221

VentureBeat's mission is to be a digital town square for technical decision-makers to gain knowledge about transformative enterprise technology and transact. Learn more about membership.

Go here to see the original:

Dubai on the Brain: NeuroVigil's Philip Low Assembles ...

Job description

This post provides an exciting opportunity to lead on the participatory research and communication of a new UKRI Network Plus (RESPECT 4 Neurodevelopment). RESPECT for Neurodevelopment stands for Responsible, Reliable, Scalable and Personalised Neurotechnology for Neurodevelopmental Conditions. Our goal is to build a multidisciplinary community to advance child-specific neurotechnologies to underpin precision medicine for neurodevelopmental conditions. To do this, we will create the first UK-based hub that brings together the major bioengineering and physics communities from academia and industry working on neuroimaging, wearable and mobile technologies (e.g., MRI, fNIRS, EEG, eye-tracking, digital technologies), neuroscientists, psychologists and psychiatrists working on early brain development and neurodevelopmental conditions, as well as neurodiverse people and families with lived experience who will use these technologies. They are joined by bioethicists who advise on the legal and ethical issues arising from these new technologies, and health care providers and policy makers who will be implementing them in the health care system.

The post-holder will be based at KCL in Dr Eva Loths group but will work closely with Prof Jones (Birkbeck University), our Ethics Advisors and a Responsibility Working Group.

Key areas include:

This post will be offered on an a fixed-term contract for 3 years/months [until May 2025]

This is a 0.5 part-time post

Key responsibilities

The above list of responsibilities may not be exhaustive, and the post holder will be required to undertake such tasks and responsibilities as may reasonably be expected within the scope and grading of the post.

Skills, knowledge, and experience

Essential criteria

Desirable criteria

Further information

This post is subject to Disclosure and Barring Service clearance.

See the article here:

Research Associate: Participatory Research and Communications Officer job with KINGS COLLEGE LONDON | 292429 - Times Higher Education

Face Recognition Software Market Overview 2022

This has brought along several changes in This report also covers the impact of COVID-19 on the global market.

The report offers detailed coverage of Face Recognition Software industry and main market trends. The market research includes historical and forecast market data, demand, application details, price trends, and company shares of the leading Face Recognition Software by geography. The report splits the market size, by volume and value, on the basis of application type and geography.

The Top key vendors in Face Recognition Software Market include are:- Aware (US), BioID (DE), Idemia (FR), Leidos (US), Visage Technologies (SE), Cloudwalk (CN), M2SYS (US), Gemalto (NZ), StereoVision Imaging (US), Cognitec Systems (GE), HID Global (US), NEC (JP), NVISO (BE), Daon (US), MEGVII (CN), Ayonix Face Technologies (IN), Innovatrics (SK), HYPR (US), Fujitsu (JP), Kairos (US), Animetrics (US), id3 Technologies (FR), Smilepass (GB), Techno Brain (SA), Neurotechnology (LT), Fulcrum Biometrics (US), FaceFirst (US), Certibio (BR)

Get a Sample PDF copy of this Face Recognition Software Market Report @ https://www.reportsinsights.com/sample/643777

This research report categorizes the global Face Recognition Software market by top players/brands, region, type and end user. This report also studies the global Face Recognition Software market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

Major Product Types covered are:Holistic Matching Methodfeature-based MethodSkin Texture AnalysisHybrid TypesOther

The Application Coverage in the Market are: Corporate & Residential SecurityPublic TransportEntertainment SoftwarePublic Security & JusticeSelf-service EquipmentAttendance & ConferenceFinancial ServicesOther

Region wise performance of the Face Recognition Software industry

This report studies the global Face Recognition Software market status and forecast, categorizes the global Cable Conduits market size (value & volume) by key players, type, application, and region. This report focuses on the top players in North America, Europe, China, Japan, Southeast Asia India and Other regions (Middle East & Africa, Central & South America).

To get this report at a profitable rate.: https://www.reportsinsights.com/discount/643777

The study objectives of this report are:

Scope of the Report:-

The report scope combines a detailed research of Global Face Recognition Software Market 2022 with the apprehension given in the advancement of the industry in certain regions.

The Top Companies Report is designed to contribute our buyers with a snapshot of the industrys most influential players. Besides, information on the performance of different companies, profit, gross margin, strategic initiative and more are presented through various resources such as tables, charts, and info graphic.

Access full Report Description, TOC, Table of Figure, Chart, etc. @ https://www.reportsinsights.com/industry-forecast/face-recognition-software-market-analysis-by-regions-643777

About US:

Reports Insights is the leading research industry that offers contextual and data-centric research services to its customers across the globe. The firm assists its clients to strategize business policies and accomplish sustainable growth in their respective market domain. The industry provides consulting services, syndicated research reports, and customized research reports.

Contact US:

Email:info@reportsinsights.com

Sales:sales@reportsinsights.com

Continued here:

Face Recognition Software Market 2022: Size, Industry Share, Approaches, and Forecast By 2028, (Idemia (FR), Aware (US), Leidos (US), BioID (DE)) ...

Elon Musk may be keen on buying Twitter, but investors are less excited. Last Tuesday the day after Twitter agreed to Musks $44 billion (41 billion) takeover offer Tesla shares tanked 12 per cent, with the electric car giant losing over $125 billion in market value.

Musks Twitter deal was not the sole reason for the sell-off growth stocks everywhere were slaughtered that day but its clear there is much scepticism about the wisdom of the move.

Back in 2015, Musk said he wouldnt recommend running two companies, saying it decreases your freedom quite a lot. If the Twitter deal goes ahead, however, he would be running five companies Tesla, Twitter, aerospace outfit SpaceX, engineering firm the Boring Company, and neurotechnology company Neuralink. Little wonder multiple Tesla analysts questioned whether Musk is spreading himself too thin.

Shareholders are also wary Musk may end up selling Tesla shares to get the deal done. Musk pledged Tesla shares in order to secure the necessary bank loans. According to Bloomberg calculations, he will need to add more money to meet margin requirements if Tesla shares, which traded around $880 last week, fall below $740.

Is Twitter really worth the hassle? Twitter is a slow-growing, money-losing, 16-year-old firm that couldnt find a rival bidder to Musk, even though his offer price was almost 30 per cent below last years high.

Dont be surprised if Musk ends up having second thoughts. Last week, Twitter shares were trading some 10 per cent below Musks offer price, indicating markets are sceptical as to whether this deal will ultimately get done.

View original post here:

Stocktake: Investors wary on Musk's Twitter deal - The Irish Times

Hydrocolloid Dressing Market

Albany NY, United States: The increasing predominance of street accidents all around the world, of hydrocolloid dressing. This is on account of its advantages, expanded focal point of innovative progressions associated with the assembling of clinical gadgets, and rising use on the medical care foundation advancement, particularly in the creating economies. Use hydrocolloid dressings can be used on various wounds as it is most effective on wounds with low to moderate drainage. Mechanical progression in dressing innovations and flood in mindfulness in regards to the adequacy of hydrocolloid dressing is required to drive the market. Additionally, expanded reception of hydrocolloid dressing is required to support market development.

Upsurge in the mindfulness in regards to the viability of hydrocolloid dressing among the populace combined with the rising frequency of consuming wounds is one of the central points encouraging the development of the hydrocolloid dressing market. The rising approach of different advancements and exploration in the field of medical services to foster the innovation associated with dressing and rising individual extra cash are some other circuitous hydrocolloid dressing market development determinants. Developing utilization of hydrocolloid dressing combined with expanding instances of persistent, careful, and horrendous injuries will additionally create lucrative growth opportunities for this market in the future.

Request a report brochure to gain comprehensive insights at:

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=69134

Hydrocolloid Dressing Market: Introduction

Hydrocolloid dressing is a wafer type of dressing that contains gel-forming agents with an adhesive compound laminated into a flexible, water-resistant outer layer. Some formulation contains alginate to increase absorption capabilities. The wafers are self-adhering and available with or without an adhesive border. The wafers are available in various thickness and precut shapes for body area such as sacrum, elbows, and heels.

The wafers provide a moist healing environment and insulation while using the bodys own moisture and enzymes to keep the wound bed hydrated for proper wound healing. The hydrocolloid dressings can be used on many different types of wounds which have the best effects and have low to moderate drainage. Clinicians often suggest hydrocolloid dressings for granular and necrotic wounds, as the products protect intact and newly healed skin.

Request for Covid-19 Impact Analysis:

https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=69134

Hydrocolloid Dressing Market: Competitive Landscape

Major players operating in the global hydrocolloid dressing market include Cardinal Health, Smith & Nephew, Acelity L.P., Inc., Medela AG, BenQ Materials Corporation, EuroMed, Inc., Advanced Medical Solutions Group plc, and ConvaTec, Inc.

Smith & Nephew

Founded in 1937, Smith & Nephew plc is a medical technology company engaged in the development, manufacture, and commercialization of medical devices worldwide.

The company offers various product franchises, including orthopedic implants (knee implants, hip implants), arthroscopy enabling technologies, trauma and extremities, advanced wound care, advanced wound devices, and advanced wound bioactives.

For any Queries Related with the Report, Ask an Analyst:

https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=69134

Cardinal Health

Established in 1979, Cardinal Health is a global, integrated health care services and products company, providing customized solutions worldwide.

The companys medical segment distributes a broad range of medical, surgical, and laboratory products and provides services to hospitals, ambulatory surgery centers, and clinical laboratories.

Stryker Corporation

Established in 1941, Stryker Corporation is a global medical device company. It operates through three business segments: Orthopedics, MedSurg, and neurotechnology & spine.

The companys product portfolio includes implants, surgical equipment, endoscopic and communication systems, neurosurgical and spinal devices, and emergency medical equipment.

Hydrocolloid Dressing Market Dynamics

Increase in incidences of target diseases driving demand for hydrocolloid dressing

The increasing number of cardiovascular diseases, neurovascular diseases, and glaucoma may boost the use of hydrocolloid dressing devices in specific surgeries. The rise in number of cardiovascular diseases increases the demand for open heart surgery which is likely to expand the global market.

Rise in geriatric population leads to number of diseases which demands hydrocolloid dressing products

The rapid growth in geriatric population leads to diseases such as eye diseases, cardiovascular diseases, and neurological disorders which has increased the number of surgeries globally.

According to The American Geriatrics Society, adults of age 65 and older are a rapidly growing segment of the U.S. population, and their number is expected to double to 89 million people between 2010 and 2050. Based on these evolving demographics, demand for a variety of surgical services is estimated to rise, including vascular surgery with a projected growth of 31% and general surgery with a projected growth of 18%.

Lack of clinical knowledge and expertise restraining hydrocolloid dressing market

A key factor hampering the hydrocolloid dressing market is lack of clinical knowledge and expertise in handling the hydrocolloid dressing products. Lack of knowledge and expertise leads to several complications such as the disparate approaches taken in wound management practices. This is likely to restrain the adoption of hydrocolloid dressing during surgeries.

More Trending Reports by Transparency Market Research:

Anti-biofilm Wound Dressing Market: The rise in the occurrence of chronic illnesses such as diabetes and cancer throughout the world is driving expansion of the global anti-biofilm wound dressing market. Non-communicable illnesses are becoming more prevalent due to various factors such as smoking, alcohol usage, antibiotic resistance, and unhealthy and sedentary lifestyles.

Advanced Wound Dressing Market: Advanced wound care products have been increasing clinical significance on the back of growing indications for their use, notably in chronic diseases. Their popularity for non-healing diabetic, venous, and arterial ulcers is also a robust undercurrent to their potential in advanced wound dressing market.

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

Contact

Rohit BhiseyTransparency Market ResearchState Tower,90 State Street,Suite 700,Albany NY - 12207United StatesUSA - Canada Toll Free: 866-552-3453Email: sales@transparencymarketresearch.comWebsite: https://www.transparencymarketresearch.com/

Go here to read the rest:

Hydrocolloid Dressing Market Competitive Landscape Analysis With Forecast by 2027 - BioSpace